News Archive

JENKINTOWN, PA, UNITED STATES, April 8, 2021 /EINPresswire.com/ — SFA Therapeutics, Inc., a clinical-stage biotechnology company, is pleased to announced the start…

April 8, 2021

The 10 Most Promising Biotech Startups in the United States

CEO LEADERSHIP SERIES: IRA C. SPECTOR, PH.D., CEO, SFA THERAPEUTICS

And the 2018 Stellar StartUps Finalists are

SFA Therapeutics Wins U.S. Patent for Use of Short Chain Fatty Acids in Cancer Prevention

Helsinn Investment Fund: 10 finalists for Lyfebulb-Helsinn innovation summit & awards in oncology

SFA Therapeutics Wins Second Key U.S. Patent For Treatment of Chronic Liver Diseases

SFA Therapeutics to Present Human Psoriasis Data for Microbiome-based Drug (SFA002) at the Global Biotech Entrepreneur Forum and the BIO International Convention

SFA Therapeutics to Present Human Psoriasis Data for Microbiome-based Drug (SFA002) at the Global Biotech Entrepreneur Forum and the BIO International Convention

SFA Therapeutics, Inc. Requests FDA Orphan Drug Designation (ODD) for SFA001 for Treatment of Hepatocellular Carcinoma (HCC)

Innovations in Dermatological Sciences

Inside the Patient Entrepreneur’s Mind: Ira Spector, PhD

Student Analyzes Potential for a Startup’s Drugs

SFA Therapeutics, Inc. To Present At The Microbiome R&D and Business Collaboration Forum

SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)

The Future Is Bright For Microbiome Metabolites And Drugs Derived From Probiotics

Endless Frontier Labs at New York University’s Stern School of Business Graduates its 2019-2020 Cohort of Startups

Melior Discovery Announces Partnership with SFA on Grant Directed to COVID-19

SFA Therapeutics Announces FDA Approval To Begin IND Trial

SFA THERAPEUTICS INVITED TO PRESENT AT ANGEL VENTURE FAIR

Houston organization names 10 most promising life sciences startups

SFA THERAPEUTICS, INC. ANNOUNCES START OF PHASE 1b CLINICAL TRIAL IN THE TREATMENT OF MILD-to-MODERATE PLAQUE PSORIASIS

SFA THERAPEUTICS, INC. ANNOUNCES START OF PHASE 1b CLINICAL TRIAL IN THE TREATMENT OF MILD-TO-MODERATE PLAQUE PSORIASIS

Announcing BioNJ’s BioPartnering Company & Pitch Presentation Award Honorees

SFA Therapeutics Selected as 2021 Company and Pitch Presentation Award Honoree at 11th Annual BioPartnering Conference

SFA Therapeutics Accepted To The Y-Combinator Accelerator Summer Cohort 2021

2021 Most Fundable Company

SFA Therapeutics Ranked Most Fundable Company by Pepperdine Graziadio Business School

Mr. Shawn Patrick OBrien joins SFA Therapeutics as a Strategic Advisor and Chairman

Pismo Ventures’ National Venture Plan Startup Competition Announces Winners

SFA THERAPEUTICS, INC. CLOSES SEED ROUND RAISE of $4M

A completely new approach to drug discovery and development.

QUICK LINKS

CONTACT

Select Sidearea

News Archive

A completely new approach to drug discovery and development.

QUICK LINKS

CONTACT